Annals of Oncology 6:355-362, 1995
© 1995 European Society for Medical Oncology
research-article |
Gastric B-cell mucosa-associated lymphoid tissue (MALT) lymphoma. Clinicopathological study and evaluation of the prognostic factors in 143 patients
1Department of Internal Medicine, Hospital Ramón y Cajal, Universidad de Alcalà de Henares Madrid
4Department of Pathology, Hospital Ramón y Cajal, Universidad de Alcalà de Henares Madrid
8Department of Hematology, Hospital Ramón y Cajal, Universidad de Alcalà de Henares Madrid
3Department of Clinical Epidemiology and Biostatistics Unit, Hospital Ramón y Cajal, Universidad de Alcalà de Henares Madrid
2Department of Internal Medicine, Fundaciòn Jimenez Diaz, Universidad Autonoma Madrid
10Department of Pathology, Fundaciòn Jimenez Diaz, Universidad Autonoma Madrid
7Department of Oncology, Hospital Virgen de la Salud Toledo
5Department of Pathology, Hospital Virgen de la Salud Toledo
6Department of Oncology, Hospital Gregorio Marahon, Universidad Complutense Madrid, Spain
9Department of Pathology, Hospital Gregorio Marahon, Universidad Complutense Madrid, Spain
Correspondence to: Dr. C. Montalbàn, Department of Internal Medicine, Hospital Ramon y Cajal, Carretera de Colmenar Km 9, Madrid 28034, Spain
BACKGROUND: Gastric MALT lymphoma can be histologically classified into two groups, low-grade (LG) and high-grade (HG); however, their natural history is poorly understood. We have studied a large retrospective series aiming to confirm whether the histological groups confer different clinical features and behavior and to analyze the prognostic factors in these patients.
PATIENTS AND METHODS: A series of 143 gastric B-cell MALT lymphomas is reported. Eighty-four were low-grade lymphomas (LG) and 59 were high-grade lymphomas (HG). Median follow-up was 36 months. The clinical and analytical parameters of the 84 LG patients were compared with those of the 59 HG patients. In the patients who had been operated on, the pathological features (macroscopical patterns, tumor size, involvement of resection margins, degree of parietal invasion and involvement of abdominal lymph nodes and adjacent viscera) of the LG patients were compared with those of the HG patients. The sites of relapses were studied. In the 132 treated and followed-up patients the influence of the treatment and that of clinical, analytical and pathological features on survival were investigated with the Kaplan and Meier and log-rank tests. To identify the factors with independent influence on survival, a Cox model was fitted for the whole series and separately for 53 HG patients.
RESULTS: HG group differed from the LG group by a significantly higher frequency of weight loss at presentation, palpable abdominal mass, hepatomegaly, peripheral lymphadenopathy, elevated serum LDH, higher incidence of stage m-IV and tumor/mass patterns in the endoscopy and in the gastrectomy specimen. The tumor was significantly larger in the HG group than in the LG and the deeper invasion of the gastric wall, the higher frequency of infiltration of the abdominal lymph nodes and the visceral extension were also significant in the HG group. Complete remission (CR) was achieved in 91 of the patients of the LG group, but was significantly lower, 70%, in the HG group. Relapses occurred in the stomach and also in non-MALT sites. In 132 treated and followed-up patients, elevated serum LDH, absence of CR, HG group and stage in-IV were associated with a worse survival. In the Cox multivariate model, stage was the only variable influencing survival, although stage was related to the histological grade. In the HG group, stage was also an independent significant risk factor, whereas treatment with surgery, chemotherapy or both was not. In the 103 patients treated with surgery, a worse survival was associated with the involvement of the resection borders, depth of the infiltration of the gastric wall, dissemination to distant abdominal nodes and adjacent organs, but not with the addition of chemotherapy.
CONCLUSIONS: Histological classification into LG and HG separates distinctive groups of gastric MALT lymphoma that show striking clinical and prognostic differences. Besides histological grade, stage is the most important prognostic feature.
gastric lymphoma, lymphoma, MALT lymphoma, prognostic factors
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. G. Gobbi, F. Corbella, F. Valentino, M. Bergonzi, C. Sangalli, V. Perfetti, and G. R. Corazza Complete long-term response to radiotherapy of gastric early-stage marginal zone lymphoma resistant to both anti-Helicobacter pylori antibiotics and chemotherapy Ann. Onc., March 1, 2009; 20(3): 465 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Papaxoinis, G. Fountzilas, D. Rontogianni, M. A. Dimopoulos, N. Pavlidis, C. Tsatalas, D. Pectasides, N. Xiros, and T. Economopoulos Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG) Ann. Onc., April 1, 2008; 19(4): 780 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M Bacon, M.-Q. Du, and A. Dogan Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists J. Clin. Pathol., April 1, 2007; 60(4): 361 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Alam, K. Frahad, P. A. Griffiths, and M. Hurley Simultaneous Gastrointestinal Stromal Tumor and Mucosa-Associated Lymphoid Tissue Lymphoma of the Stomach J. Clin. Oncol., March 20, 2007; 25(9): 1136 - 1138. [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Cohen, M. Petryk, M. Varma, P. S. Kozuch, E. D. Ames, and M. L. Grossbard Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue Oncologist, November 1, 2006; 11(10): 1100 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Suzuki, K. Matsuo, H. Ito, K. Hirose, K. Wakai, T. Saito, S. Sato, Y. Morishima, S. Nakamura, R. Ueda, et al. A past history of gastric ulcers and Helicobacter pylori infection increase the risk of gastric malignant lymphoma Carcinogenesis, July 1, 2006; 27(7): 1391 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Thieblemont Clinical Presentation and Management of Marginal Zone Lymphomas Hematology, January 1, 2005; 2005(1): 307 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wohrer, A. Puspok, J. Drach, M. Hejna, A. Chott, and M. Raderer Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma Ann. Onc., July 1, 2004; 15(7): 1086 - 1090. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-S. Park, K. W. Kim, J.-S. Yu, C. Park, J. K. Kim, S.-W. Yoon, K.-H. Lee, Y. H. Ryu, H. Kim, M.-J. Kim, et al. Radiographic Findings of Primary B-Cell Lymphoma of the Stomach: Low-Grade Versus High-Grade Malignancy in Relation to the Mucosa-Associated Lymphoid Tissue Concept Am. J. Roentgenol., November 1, 2002; 179(5): 1297 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Jager, P. Neumeister, R. Brezinschek, T. Hinterleitner, W. Fiebiger, M. Penz, H. J. Neumann, B. Mlineritsch, M. DeSantis, F. Quehenberger, et al. Treatment of Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue Type With Cladribine: A Phase II Study J. Clin. Oncol., September 15, 2002; 20(18): 3872 - 3877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Raderer, A. Chott, J. Drach, C. Montalban, B. Dragosics, U. Jager, A. Puspok, C. Osterreicher, and C. C. Zielinski Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary? Ann. Onc., July 1, 2002; 13(7): 1094 - 1098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Ranaldi, G Goteri, M G Baccarini, B Mannello, and I Bearzi A clinicopathological study of 152 surgically treated primary gastric lymphomas with survival analysis of 109 high grade tumours J. Clin. Pathol., May 1, 2002; 55(5): 346 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. An, J. K. Han, Y. H. Kim, A. Y. Kim, B. I. Choi, Y. A Kim, and C. W. Kim Gastric Mucosa-associated Lymphoid Tissue Lymphoma: Spectrum of Findings at Double-Contrast Gastrointestinal Examination with Pathologic Correlation RadioGraphics, November 1, 2001; 21(6): 1491 - 1502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cavalli, P. G. Isaacson, R. D. Gascoyne, and E. Zucca MALT Lymphomas Hematology, January 1, 2001; 2001(1): 241 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Zucca, F. Bertoni, E. Roggero, and F. Cavalli The gastric marginal zone B-cell lymphoma of MALT type Blood, July 15, 2000; 96(2): 410 - 419. [Full Text] [PDF]
|
|
|
|
|
|
C. Thieblemont, F. Berger, C. Dumontet, I. Moullet, F. Bouafia, P. Felman, G. Salles, and B. Coiffier Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed Blood, February 1, 2000; 95(3): 802 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. N. Nathwani, J. R. Anderson, J. O. Armitage, F. Cavalli, J. Diebold, M. R. Drachenberg, N. L. Harris, K. A. MacLennan, H. K. Muller-Hermelink, F. A. Ullrich, et al. Marginal Zone B-Cell Lymphoma: A Clinical Comparison of Nodal and Mucosa-Associated Lymphoid Tissue Types J. Clin. Oncol., August 1, 1999; 17(8): 2486 - 2486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Steinbach, R. Ford, G. Glober, D. Sample, F. B. Hagemeister, P. M. Lynch, P. W. McLaughlin, M. A. Rodriguez, J. E. Romaguera, A. H. Sarris, et al. Antibiotic Treatment of Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue: An Uncontrolled Trial Ann Intern Med, July 20, 1999; 131(2): 88 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Villuendas, M. Sanchez-Beato, J. C. Martinez, A. I. Saez, B. Martinez-Delgado, J. F. Garcia, M. S. Mateo, L. Sanchez-Verde, J. Benitez, P. Martinez, et al. Loss of p16/INK4A Protein Expression in Non-Hodgkin's Lymphomas Is a Frequent Finding Associated with Tumor Progression Am. J. Pathol., September 1, 1998; 153(3): 887 - 897. [Abstract] [Full Text] [PDF]
|
|